Abstract
Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improved homologous recombination deficiency test must be developed and alternative treatments defined for these subsets of patients.
Original language | English (US) |
---|---|
Pages (from-to) | 4-6 |
Number of pages | 3 |
Journal | Nature Reviews Urology |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2019 |
ASJC Scopus subject areas
- Urology